Detalles de la búsqueda
1.
[Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]. / Effektivnost' i bezopasnost' dvukhletnei terapii divozilimabom u patsientov s rasseyannym sklerozom v ramkakh randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya BCD-132-4/MIRANTIBUS.
Zh Nevrol Psikhiatr Im S S Korsakova
; 124(4): 86-96, 2024.
Artículo
en Ruso
| MEDLINE | ID: mdl-38676683
2.
[Long-term Efficacy and Safety of Sampeginterferon-ß1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results]. / Dolgosrochnye dannye po effektivnosti i bezopasnosti preparata sampeginterferon-ß1a u patsientov s remittiruyushchim rasseyannym sklerozom: rezul'taty 104-nedel'nogo randomizirovannogo dvoinogo slepogo klinicheskogo issledovaniya.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(2): 52-59, 2023.
Artículo
en Ruso
| MEDLINE | ID: mdl-36843459
3.
[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]. / Effektivnost' i bezopasnost' 48 nedel'nogo primeneniya monoklonal'nogo antitela protiv CD20 divozilimaba u patsientov s rasseyannym sklerozom: rezul'taty randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya BCD-132-4/MIRANTIBUS.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(7. Vyp. 2): 43-52, 2023.
Artículo
en Ruso
| MEDLINE | ID: mdl-37560833
4.
[Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2]. / Effektivnost' i bezopasnost' 24 nedel' primeneniya divozilimaba sredi patsientov s rasseyannym sklerozom v ramkakh randomizirovannogo dvoinogo slepogo platsebo-kontroliruemogo klinicheskogo issledovaniya BCD-132-2.
Zh Nevrol Psikhiatr Im S S Korsakova
; 123(4): 37-47, 2023.
Artículo
en Ruso
| MEDLINE | ID: mdl-37084363
5.
[Efficacy and safety of sampeginterferon ß-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial]. / Effektivnost' i bezopasnost' sampeginterferona ß-1a dlya lecheniya remittiruyushchego rasseyannogo skleroza: rezul'taty 52-nedel'nogo randomizirovannogo dvoinogo slepogo klinicheskogo issledovaniya.
Zh Nevrol Psikhiatr Im S S Korsakova
; 122(1): 62-71, 2022.
Artículo
en Ruso
| MEDLINE | ID: mdl-35175704
6.
[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].
Mol Biol (Mosk)
; 45(6): 963-72, 2011.
Artículo
en Ruso
| MEDLINE | ID: mdl-22295566
7.
[Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety]. / Rezul'taty I fazy klinicheskogo issledovaniia monoklonal'nogo antitela protiv CD20 (BCD-132): farmakokinetika, farmakodinamika i bezopasnost'.
Zh Nevrol Psikhiatr Im S S Korsakova
; 119(10. Vyp. 2): 87-95, 2019.
Artículo
en Ruso
| MEDLINE | ID: mdl-31934993
8.
[Experience of using interferon Β-1a biosimilans (cinnovex and genfaxon-44) in the Moscow Multiple Sclerosis Center]. / Opyt primeneniia bioanalogov Β-interferona-1a - sinnoveksa i genfaksona-44 v Moskovskom gorodskom tsentre rasseiannogo skleroza.
Zh Nevrol Psikhiatr Im S S Korsakova
; 115(2 Pt 2): 51-56, 2015.
Artículo
en Ruso
| MEDLINE | ID: mdl-26081337
9.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
Zh Nevrol Psikhiatr Im S S Korsakova
; 113(10 Pt 2): 93-6, 2013.
Artículo
en Ruso
| MEDLINE | ID: mdl-24300821
10.
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Zh Nevrol Psikhiatr Im S S Korsakova
; 112(5): 56-61, 2012.
Artículo
en Ruso
| MEDLINE | ID: mdl-22951783
11.
[Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center].
Zh Nevrol Psikhiatr Im S S Korsakova
; 112(2 Pt 2): 86-92, 2012.
Artículo
en Ruso
| MEDLINE | ID: mdl-22677683
12.
[The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis].
Zh Nevrol Psikhiatr Im S S Korsakova
; 112(2 Pt 2): 98-103, 2012.
Artículo
en Ruso
| MEDLINE | ID: mdl-22677685
13.
[The use of rebif in the Moscow Municipal Multiple Sclerosis Center].
Zh Nevrol Psikhiatr Im S S Korsakova
; 111(2 Pt 2): 68-71, 2011.
Artículo
en Ruso
| MEDLINE | ID: mdl-21916159
14.
[Data of MRI and neuropsychological tests predict the course of typical remitting multiple sclerosis during five years].
Zh Nevrol Psikhiatr Im S S Korsakova
; 111(2 Pt 2): 29-37, 2011.
Artículo
en Ruso
| MEDLINE | ID: mdl-21919232
15.
[The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: issues of efficacy and adherence to therapy].
Zh Nevrol Psikhiatr Im S S Korsakova
; Spec No 3: 101-10, 2006.
Artículo
en Ruso
| MEDLINE | ID: mdl-17172244
Resultados
1 -
15
de 15
1
Próxima >
>>